News

22 November, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Brad Hoy, Chief Financial Officer (CFO), and Dr Craig Fox, Chief Scientific Officer (CSO), will join the Board of Directors with immediate effect. In addition, Brad Hoy has been appointed permanent CFO today following a period as interim CFO.

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that the Company has entered into a multi-target, risk-sharing alliance ("the Agreement") with Evotec AG ("Evotec"), a leading drug discovery alliance and development partnership company. The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development, with the initial programmes targeted towards the treatment of cancer and autoimmune diseases.

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

Calculus Capital Limited and Polar Capital LLP to join share register

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that it has raised £5.0 million before expenses (the "Placing") via a conditional placing of 4,901,961 new ordinary shares (the "Placing Shares") to current and new investors, through Zeus Capital as nominated adviser and broker to the Company, at a placing price of 102p (the “Placing Price”) per ordinary share.

The company has acquired “a virtual library of over a billion molecules”, which should give the company a boost when it starts new discovery programmes.

According to Dr Clive Dix, the chief executive officer of C4X, the newly acquired software is “all about optimising those molecules that we find by using our other technologies”.

Dr Dix told Proactive Investors: “Everything we do is aimed at reducing the time and the cost of getting to the clinical trial and then … with the molecules we have being of higher quality, they’ll be more likely to be successful in the trials.”
The company will be starting new projects on a regular basis and when the time is right will decide on a case-by-case basis whether to bring in a partner or take the drugs to clinical trial independently.

Proprietary platform technology further augments C4X Discovery’s drug discovery engine

12th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the "Molplex Technologies").

Taxonomy 3 analyses publicly available databases to identify previously unknown linkages between genes and diseases.

C4X Discovery Holdings (LON:C4XD) chief executive Clive Dix said the company had studied rheumatoid arthritis and Parkinson's disease data. "What we have found are genes that are highly associated with these diseases."

~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~

4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.